Publication:
Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms

Simple item page
dc.contributor.coauthorKaymaz-Tahra, Sema
dc.contributor.coauthorTsechelidis, Ozun Bayindir
dc.contributor.coauthorInce, Burak
dc.contributor.coauthorOzdemir-Isik, Ozlem
dc.contributor.coauthorKutu, Muhammet Emin
dc.contributor.coauthorKarakas, Ozlem
dc.contributor.coauthorDemirci-Yildirim, Tuba
dc.contributor.coauthorAdemoglu, Zeliha
dc.contributor.coauthorEdiboglu, Elif
dc.contributor.coauthorUludogan, Burcu Ceren
dc.contributor.coauthorBile, Nazife Sule Yasar
dc.contributor.coauthorKasifoglu, Timucin
dc.contributor.coauthorAkar, Servet
dc.contributor.coauthorEmmungil, Hakan
dc.contributor.coauthorOnen, Fatos
dc.contributor.coauthorOmma, Ahmet
dc.contributor.coauthorYazici, Ayten
dc.contributor.coauthorCefle, Ayse
dc.contributor.coauthorInanc, Murat
dc.contributor.coauthorAksu, Kenan
dc.contributor.coauthorKeser, Gokhan
dc.contributor.coauthorDireskeneli, Haner
dc.contributor.coauthorOner, Fatma Alibaz
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanıtez, Nilüfer Alpay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:57:29Z
dc.date.issued2024
dc.description.abstractBackground/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to assess the characteristics of TAK patients needed biologic treatment during follow-up in daily practice.
dc.description.indexedbyWOS
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.eissn2326-5205
dc.identifier.issn2326-5191
dc.identifier.quartileQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27251
dc.identifier.volume76
dc.identifier.wos1331419108007
dc.keywordsTakayasu’s arteritis
dc.keywordsBiologic immunosuppressive treatment
dc.keywordsPatient characteristics
dc.keywordsFollow-up
dc.keywordsDaily practice
dc.keywordsBiologic therapy
dc.keywordsTreatment selection
dc.keywordsArteritis management
dc.keywordsImmunosuppressive therapy
dc.keywordsChronic disease management
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofARTHRITIS and RHEUMATOLOGY
dc.subjectRheumatology
dc.titleBiological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms
dc.typeOther
dc.type.otherMeeting abstract
dspace.entity.typePublication
local.contributor.kuauthorKanıtez, Nilüfer Alpay
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext